Targets › FYN
1 program from 1 company in 5 trials: 4 Phase 2, 1 Phase 3; Immunology; next expected readout Nov 2026.
Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. (UniProt, P06241)
Open in Phaseline: the race on FYN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing InnoCare Pharma Tech | ICP-332 Spleen tyrosine kinase (SYK) inhibitor | FYN | Phase 3 | Atopic Dermatitis; Prurigo Nodularis (PN); Plaque Psoriasis; Chronic Spontaneous Urticaria (CSU) … | Nov 2026 |
Atopic Dermatitis (1) Prurigo Nodularis (PN) (1) Plaque Psoriasis (1) Chronic Spontaneous Urticaria (CSU) (1) Non Segmental Vitiligo (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.